Seeking Alpha
03 Sept 2026, 13:48 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
ELVN-001 demonstrated a 61% Major Molecular Response (MMR) rate at 80 mg daily in Phase 1 trials. — Strong clinical efficacy in early phases is the primary driver of valuation and success probability for biotech assets.
+0.60Enliven Therapeutics holds $895M in cash, providing a funding runway into 2030. — Substantial capitalization eliminates immediate dilution risk and ensures the completion of the pivotal ENABLE-2 trial.
+0.40ELVN-001 is being positioned for use in earlier-line chronic myeloid leukemia (CML) settings. — Expanding the addressable market to earlier-line treatment significantly increases the potential peak sales of the drug.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is well-capitalized with strong Phase 1 data and a clear clinical pathway for its lead candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
5h ago
